ESMO: Padcev/Keytruda Combo Edges Closer To First-Line Bladder Cancer Filing
Big Boost For Seagen
Executive Summary
Full data presented at ESMO from a closely watched trial of Seagen/Astellas’s Padcev and Merck & Co’s Keytruda should support regulatory approval of the combination in cisplatin-ineligible first-line metastatic urothelial cancer patients but concerns over duration of treatment remain.
You may also be interested in...
Early Data For Bicycle’s Nectin-4 Asset Shows Promising Duration In Urothelial Cancer
The UK-headquartered biotech’s peptide-toxin conjugate showed a prolonged duration of response in advanced urothelial cancer patients in an early-stage trial compared with current standard of care, raising hopes for a differentiated profile.
Investors Cool On Seagen As Merck & Co Merger Hopes Fade
After more than three months of speculation about a possible Merck & Co buyout, the chatter has gone quiet – but the deal might not be dead yet.
Seagen Talks Up 24% Growth, Not About Speculated Merck Buyout
The Seattle-based biotech reported a 24% increase in product sales in the second quarter amid speculation that Merck is about to acquire the company.